WO2003008930A3 - Lfa-1 binding agents that recognize neoepitopes - Google Patents

Lfa-1 binding agents that recognize neoepitopes Download PDF

Info

Publication number
WO2003008930A3
WO2003008930A3 PCT/US2002/022482 US0222482W WO03008930A3 WO 2003008930 A3 WO2003008930 A3 WO 2003008930A3 US 0222482 W US0222482 W US 0222482W WO 03008930 A3 WO03008930 A3 WO 03008930A3
Authority
WO
WIPO (PCT)
Prior art keywords
lfa
binding agents
recognize
neoepitopes
recognize neoepitopes
Prior art date
Application number
PCT/US2002/022482
Other languages
French (fr)
Other versions
WO2003008930A2 (en
Inventor
Chan Beals
Original Assignee
Icos Corp
Chan Beals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp, Chan Beals filed Critical Icos Corp
Priority to AU2002324504A priority Critical patent/AU2002324504A1/en
Publication of WO2003008930A2 publication Critical patent/WO2003008930A2/en
Publication of WO2003008930A3 publication Critical patent/WO2003008930A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides antibodies that specifically recognize and bind activated LFA-1 irrespective of LFA-1 ligand binding.
PCT/US2002/022482 2001-07-16 2002-07-16 Lfa-1 binding agents that recognize neoepitopes WO2003008930A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002324504A AU2002324504A1 (en) 2001-07-16 2002-07-16 Lfa-1 binding agents that recognize neoepitopes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30582601P 2001-07-16 2001-07-16
US60/305,826 2001-07-16

Publications (2)

Publication Number Publication Date
WO2003008930A2 WO2003008930A2 (en) 2003-01-30
WO2003008930A3 true WO2003008930A3 (en) 2003-12-18

Family

ID=23182524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/022482 WO2003008930A2 (en) 2001-07-16 2002-07-16 Lfa-1 binding agents that recognize neoepitopes

Country Status (2)

Country Link
AU (1) AU2002324504A1 (en)
WO (1) WO2003008930A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2017044859A1 (en) * 2015-09-10 2017-03-16 Affigen, Inc. Sequencing-directed selection of tumor theranostics

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ELEMER G. ET AL.: "Monoclonal antibody to an activation neoepitope of alpha M beta 2 inhibits multiple alpha M beta 2 functions", J. IMMUNOL., vol. 152, no. 12, 15 June 1994 (1994-06-15), pages 5836 - 5844, XP002971439 *
HUANG ET AL.: "Folding of the beta-propeller domain of the integrin alphaL subunit is independent of the I domain and dependent on the beta2 subunit", PROC. NATL. ACAD. SCI. USA, vol. 94, no. 7, 1 April 1997 (1997-04-01), pages 3162 - 3167, XP002971437 *
KELLY ET AL.: "Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion", J. IMMUNOL., vol. 163, no. 10, 15 November 1999 (1999-11-15), pages 5173 - 5177, XP002171606 *
LU C. ET AL.: "Locking in alternate conformations of the integrin alphaLbeta2 I domain with disulfide bonds reveals functional relationships among integrin domains", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 5, 27 February 2001 (2001-02-27), pages 2393 - 2398, XP002209619 *
PETRUZZELLI L. ET AL.: "Activation of lymphocyte function-associated molecule-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) mimicked by an antibody directed against CD18", J. IMMUNOL., vol. 155, no. 2, 15 July 1995 (1995-07-15), pages 854 - 866, XP002209615 *
VAN KOOYK Y. ET AL.: "Activation of LFA-1 through a Ca2(+)-dependent epitope stimulates lymphocyte adhesion", J. CELL. BIOL., vol. 112, no. 2, 1991, pages 345 - 354, XP002971438 *

Also Published As

Publication number Publication date
WO2003008930A2 (en) 2003-01-30
AU2002324504A1 (en) 2003-03-03

Similar Documents

Publication Publication Date Title
WO2003002609A3 (en) Dual-specific ligand and its use
WO2004058821A3 (en) Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
AU2002238052A1 (en) Antibodies that bind both bcma and taci
EP1519735A4 (en) Assays and implements for determining and modulating hsp90 binding activity
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
AP2005003427A0 (en) Cannabinoid receptor ligands and uses thereof.
AP2005003466A0 (en) Cannabinoid receptor ligands and uses thereof.
EP1653801A4 (en) Altered antibodies having improved antigen-binding affinity
IL200608A0 (en) Methods for the detection of 193p1e1b protein and use of compositions containing a 193p1e1b protein or an antibody binding thereto
WO2004085478A3 (en) Improved fc fusion proteins
IL206832A0 (en) Antibodies binding an 161p2f10b epitope and uses thereof
AU2002365258A1 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
PL375064A1 (en) Treatment of renal carcinoma using antibodies against the egfr
MXPA03009251A (en) Method and catalysts for the elimination of sulfur compounds from the diesel fraction.
EP1581096A3 (en) Antigen pipa and antibodies that bind thereto
WO2004046186A3 (en) Intrabodies against the oncogenic form of ras
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
EP1581096A4 (en) Antigen pipa and antibodies that bind thereto
WO2004046188A3 (en) Anti-activated ras antibodies
AU2002359495A8 (en) Anti-tnf antibodies, compositions, methods and uses
WO2002065133A3 (en) Ligands used for detecting prions
ZA200402138B (en) Catalyst and it use for improving the pour point of hydrocarbon charges.
WO2006033688A8 (en) Anti-lympho- plus anti-monocytes globulin preparation for inhibiting immune responses
WO2003008930A3 (en) Lfa-1 binding agents that recognize neoepitopes
AU2003275834A1 (en) ANTIBODIES THAT BIND alphaE INTEGRIN

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP